Cancer
FDA approves BMS’ multiple myeloma combo after it doubles progression-free survival
November 7, 2018Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, Empliciti, FDA, US, multiple myeloma, pharma
The FDA has seen fit to approve Bristol-Myers Squibb’s Empliciti (elotuzumab) intravenous injection in combination with pomalidomide and dexamethasone for …
MSD’s Keytruda/chemo combo scores first-line FDA approval in NSC lung cancer
November 1, 2018Sales and Marketing Cancer, MSD, NSCLC, keytruda, lung cancer, pharma
MSD’s blockbuster anti-PD-1 immunotherapy has secured another FDA approval, it has emerged, in combination with carboplatin and either paclitaxel or …
NICE turns down Sanofi’s Caprelsa for rare thyroid cancer
October 31, 2018Research and Development, Sales and Marketing Cancer, Caprelsa, NHS, NICE, Sanofi, UK, medullary thyroid cancer, pharma
NICE has announced its recommendation to reject Sanofi’s Caprelsa (vandetanib) for use on the NHS in the treatment of medullary …
Half of kidney cancer patients initially misdiagnosed
October 30, 2018Manufacturing and Production Cancer, Kidney cancer, NHS, UK, diagnosis
Half of kidney cancer patients are initially misdiagnosed, according to data from Kidney Cancer UK’s patient survey. Despite being the …
New $2 million programme aims at increasing diversity in cancer research
October 24, 2018Research and Development Cancer, USA, black, cancer research, diversity, latino, native american
The National Cancer Institute are developing a joint cancer drug discovery and development, and research education programme focused towards the …
Roche’s Alecensa topples Pfizer’s Xalkori in Asian patients with ALK+ advanced lung cancer
October 23, 2018Manufacturing and Production, Research and Development Alecensa, Cancer, ESMO 2018, Roche, lung cancer, pharma
Following up on the reveal of data concerning its immunotherapy Tecentriq in combination with chemotherapy in the treatment of non-small …
First-line Keytruda shows better overall survival in head & neck cancer
October 23, 2018Manufacturing and Production, Research and Development Cancer, ESMO 2018, MSD, head and neck cancer, keytruda, pharma
MSD’s Keytruda (pembrolizumab) made an impact at the European Society for Medical Oncology 2018 Congress as the company unveiled new …
Shares in Mirati plummet after disappointing Phase II trial
October 23, 2018Manufacturing and Production Cancer, Mirati, leuakemia, plummet, stocks
Shares in the California-based biotech Mirati Therapuetics plummeted on Monday after the company released disappointing results from their Phase II …
Roche’s Tecentriq+chemo boosts survival in first-line non-small cell lung cancer
October 22, 2018Research and Development, Sales and Marketing Cancer, Roche, lung cancer NSCLC, pharma, tecentriq
Roche joined other major players like Bristol-Myers Squibb in revealing strong data on their cancer immunotherapies at the European Society …
BMS’ Opdivo and Yervoy combination shows outstanding survival rate in cancer patients
October 22, 2018Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, Yervoy, melanoma, opdivo
American pharma firm Bristol-Myers Squibb have announced that more than 53% of patients with advanced melanoma, who were treated with …
MSD’s Keytruda with Pfizer’s Inlyta beats Sutent in most common kidney cancer
October 19, 2018Medical Communications, Research and Development Cancer, Kidney cancer, MSD, Pfizer, inlyta, keytruda, pharma
MSD has unveiled new Phase 3 data on its blockbuster anti-PD-1 cancer therapy Keytruda (pembrolizumab) as part of a combination, …
Novartis snaps up cancer drug developer Endocyte for $2.1 billion
October 18, 2018Research and Development, Sales and Marketing Cancer, Endocyte, Novartis, pharma
Novartis will shell out $2.1 billion to acquire cancer drug developer Endocyte in a move to leverage the company’s technology …
FDA approves Pfizer’s Talzenna for breast cancer alongside tool to identify eligible patients
October 17, 2018Research and Development, Sales and Marketing Cancer, FDA, Pfizer, Talzenna, breast cancer, pharma
Pfizer’s Talzenna (talazoparib) has secured FDA approval, it has emerged. The poly (ADP-ribose) polymerase (PARP) inhibitor is now set to …
Roche’s Kadcyla beats Herceptin breast cancer disease recurrence and death risk
October 16, 2018Manufacturing and Production, Sales and Marketing Cancer, Kadcyla, Roche, breast cancer, pharma
Roche has unveiled new data for its antibody-drug conjugate Kadcyla (trastuzumab emtansine) in the treatment of patients with HER2-positive early …
BMS’ Opdivo fails to improve overall survival in small-cell lung cancer
October 15, 2018Research and Development, Sales and Marketing BMS< Opdivo, Bristol-Myers Squibb, Cancer, lung cancer, pharma
Bristol-Myers Squibb’s Opdivo (nivolumab) failed to deliver on its primary endpoint in a Phase 3 study in small-cell lung cancer, …
Latest content
Five Facts about cardiovascular disease
